Skip to main content

Articles

Page 11 of 108

  1. Obesity and low muscle mass are associated with worse outcomes of breast cancer patients. We conducted a controlled trial to study the impact of a ketogenic diet (KD) based on natural foods versus an unspecifi...

    Authors: Rainer J. Klement, Colin E. Champ, Ulrike Kämmerer, Petra S. Koebrunner, Kelley Krage, Gabriele Schäfer, M. Weigel and Reinhart A. Sweeney
    Citation: Breast Cancer Research 2020 22:94
  2. Metaplastic breast carcinoma (MBC) is a rare histological type of breast cancer, which commonly shows resistance to standard therapies and is associated with poor prognosis. The immune microenvironment in MBC ...

    Authors: Xue Chao, Lili Liu, Peng Sun, Xia Yang, Mei Li, Rongzhen Luo, Yuhua Huang, Jiehua He and Jingping Yun
    Citation: Breast Cancer Research 2020 22:92
  3. Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the ...

    Authors: Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes and Sherene Loi
    Citation: Breast Cancer Research 2020 22:91

    The Correction to this article has been published in Breast Cancer Research 2022 24:50

  4. The Oncotype DX 21-gene Recurrence Score is a genomic-based algorithm that guides adjuvant chemotherapy treatment decisions for women with early-stage, oestrogen receptor (ER)-positive breast cancer. However, ...

    Authors: Sarah M. Bernhardt, Pallave Dasari, Joseph Wrin, Wendy Raymond, Suzanne Edwards, David Walsh, Amanda R. Townsend, Timothy J. Price and Wendy V. Ingman
    Citation: Breast Cancer Research 2020 22:90
  5. Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As s...

    Authors: Neil A. O’Brien, Martina S. J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat and Dennis J. Slamon
    Citation: Breast Cancer Research 2020 22:89
  6. Perinatal factors have been associated with some adult health outcomes, but have not been well studied in young-onset breast cancer. We aimed to evaluate the association between young-onset breast cancer and peri...

    Authors: Mary V. Diaz-Santana, Katie M. O’Brien, Aimee A. D’Aloisio, Gloria Regalado, Dale P. Sandler and Clarice R. Weinberg
    Citation: Breast Cancer Research 2020 22:88
  7. Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed...

    Authors: Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon and Elgene Lim
    Citation: Breast Cancer Research 2020 22:87
  8. Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth fa...

    Authors: Afroditi Nanou, Leonie Laura Zeune, Francois-Clement Bidard, Jean-Yves Pierga and Leonardus Wendelinus Mathias Marie Terstappen
    Citation: Breast Cancer Research 2020 22:86
  9. Invasive lobular carcinoma (ILC) accounts for 10–15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tract...

    Authors: Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich and Simon J. Johnston
    Citation: Breast Cancer Research 2020 22:85
  10. Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many geneti...

    Authors: Li Li, Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee, Ying Tan, Rachel Schiff and Xiao-Song Wang
    Citation: Breast Cancer Research 2020 22:84
  11. Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluate...

    Authors: Laura Biganzoli, Saverio Cinieri, Rossana Berardi, Rebecca Pedersini, Amelia McCartney, Alessandro Marco Minisini, Elena Rota Caremoli, Simon Spazzapan, Emanuela Magnolfi, Antonella Brunello, Emanuela Risi, Raffaella Palumbo, Silvana Leo, Marco Colleoni, Sara Donati, Sabino De Placido…
    Citation: Breast Cancer Research 2020 22:83
  12. Breast cancer cells invading the connective tissues outside the mammary lobule or duct immerse in a reservoir of extracellular matrix (ECM) that is structurally and biochemically distinct from that of their si...

    Authors: Kelsey F. Ruud, William C. Hiscox, Ilhan Yu, Roland K. Chen and Weimin Li
    Citation: Breast Cancer Research 2020 22:82
  13. Previous studies have identified and validated a risk-associated Active transcriptome phenotype commonly expressed in the cancer-adjacent and histologically normal epithelium, stroma, and adipose containing perit...

    Authors: Taekyu Kang, Christina Yau, Christopher K. Wong, John Z. Sanborn, Yulia Newton, Charlie Vaske, Stephen C. Benz, Gregor Krings, Roman Camarda, Jill E. Henry, Josh Stuart, Mark Powell and Christopher C. Benz
    Citation: Breast Cancer Research 2020 22:81
  14. The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast c...

    Authors: Madhurendra Singh, Xiaolei Zhou, Xinsong Chen, Gema Sanz Santos, Sylvain Peuget, Qing Cheng, Ali Rihani, Elias S. J. Arnér, Johan Hartman and Galina Selivanova
    Citation: Breast Cancer Research 2020 22:80
  15. We previously showed that BRCA-like profiles can be used to preselect individuals with the highest risk of carrying BRCA mutations but could also indicate which patients would benefit from double-strand break ind...

    Authors: Esther H. Lips, Anne Benard-Slagter, Mark Opdam, Caroline E. Scheerman, Jelle Wesseling, Frans B. L. Hogervorst, Sabine C. Linn, Suvi Savola and Petra M. Nederlof
    Citation: Breast Cancer Research 2020 22:79
  16. Previous studies of fatty acids and breast cancer risk have shown mixed results, which may be due in part to tumor heterogeneity. Prior research has also illustrated an important role of specific fatty acids i...

    Authors: Emma E. McGee, Claire H. Kim, Molin Wang, Donna Spiegelman, Daniel G. Stover, Yujing J. Heng, Laura C. Collins, Gabrielle M. Baker, Maryam S. Farvid, Pepper Schedin, Sonali Jindal, Rulla M. Tamimi and A. Heather Eliassen
    Citation: Breast Cancer Research 2020 22:78
  17. For patients with locally advanced estrogen receptor or progesterone receptor-positive breast cancer, neoadjuvant endocrine therapy (NET) facilitates down-staging of the tumor and increased rates of breast-con...

    Authors: Lauren I. Madigan, Phuong Dinh and J. Dinny Graham
    Citation: Breast Cancer Research 2020 22:77
  18. Early luminal breast cancer (BC) represents 70% of newly diagnosed BC cases. Among them, small (under 2 cm) BC without lymph node metastasis (classified as T1N0) have been rarely studied, as their prognosis is...

    Authors: Claire Bonneau, Antoine Eliès, Yann Kieffer, Brigitte Bourachot, Sylvain Ladoire, Floriane Pelon, Delphine Hequet, Jean-Marc Guinebretière, Christophe Blanchet, Anne Vincent-Salomon, Roman Rouzier and Fatima Mechta-Grigoriou
    Citation: Breast Cancer Research 2020 22:76
  19. PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role in breas...

    Authors: Hannah Asperger, Nadia Stamm, Berthold Gierke, Michael Pawlak, Ute Hofmann, Ulrich M. Zanger, Annamaria Marton, Robert L. Katona, Andrea Buhala, Csaba Vizler, Jan-Philipp Cieslik, Eugen Ruckhäberle, Dieter Niederacher, Tanja Fehm, Hans Neubauer and Marina Ludescher
    Citation: Breast Cancer Research 2020 22:75

    The Correction to this article has been published in Breast Cancer Research 2021 23:13

  20. Cancer cells are known to display varying degrees of metastatic propensity, but the molecular basis underlying such heterogeneity remains unclear. Our aims in this study were to (i) elucidate prognostic subtyp...

    Authors: Amin Emad, Tania Ray, Tor W. Jensen, Meera Parat, Rachael Natrajan, Saurabh Sinha and Partha S. Ray
    Citation: Breast Cancer Research 2020 22:74
  21. Studies on tumor-secreted microRNAs point to a functional role of these in cellular communication and reprogramming of the tumor microenvironment. Uptake of tumor-secreted microRNAs by neighboring cells may re...

    Authors: Thilde Terkelsen, Francesco Russo, Pavel Gromov, Vilde Drageset Haakensen, Søren Brunak, Irina Gromova, Anders Krogh and Elena Papaleo
    Citation: Breast Cancer Research 2020 22:73
  22. Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metasta...

    Authors: Martin Blohmer, Li Zhu, Jennifer M. Atkinson, Sushil Beriwal, Joshua L. Rodríguez-López, Margaret Rosenzweig, Adam M. Brufsky, George Tseng, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich and Rachel C. Jankowitz
    Citation: Breast Cancer Research 2020 22:70
  23. In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff valu...

    Authors: Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang and Lei Huo
    Citation: Breast Cancer Research 2020 22:69
  24. Breast cancer is a highly heterogeneous disease characterized by multiple histologic and molecular subtypes. While a myriad of breast cancer cell lines have been developed over the past 60 years, estrogen rece...

    Authors: Jessica Finlay-Schultz, Britta M. Jacobsen, Duncan Riley, Kiran V. Paul, Scott Turner, Andrea Ferreira-Gonzalez, J. Chuck Harrell, Peter Kabos and Carol A. Sartorius
    Citation: Breast Cancer Research 2020 22:68
  25. Obesity induces molecular changes that may favor tumor progression and metastatic spread, leading to impaired survival outcomes in breast cancer. Adenylate cyclase-associated protein 1 (CAP1), an actin regulat...

    Authors: Malin Bergqvist, Karin Elebro, Malte Sandsveden, Signe Borgquist and Ann H. Rosendahl
    Citation: Breast Cancer Research 2020 22:67
  26. Triple-negative breast cancer (TNBC) is characterized by high rates of recurrence and poor overall survival. This is due, in part, to a deficiency of targeted therapies, making it essential to identify therape...

    Authors: Melyssa S. Roberts, Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar and Ruth A. Keri
    Citation: Breast Cancer Research 2020 22:66
  27. Crown-like structures in breast adipose tissue (CLS-B), composed of necrotic adipocytes encircled by macrophages, are associated with obesity and hypothesized to worsen breast cancer prognosis; however, data a...

    Authors: Maret L. Maliniak, Aswathy Miriam Cheriyan, Mark E. Sherman, Yuan Liu, Keerthi Gogineni, Jiaqi Liu, Jiabei He, Uma Krishnamurti, Jasmine Miller-Kleinhenz, Ryan Ashiqueali, Jinjing He, Rami Yacoub and Lauren E. McCullough
    Citation: Breast Cancer Research 2020 22:65
  28. Aging is a comorbidity of breast cancer suggesting that aging-associated transcriptome changes may promote breast cancer progression. However, the mechanism underlying the age effect on breast cancer remains p...

    Authors: Xiang Gu, Bingzhi Wang, Haiyan Zhu, You Zhou, Aaron M. Horning, Tim H-M Huang, Yidong Chen, Peter Houghton, Zhao Lai, Joel E. Michalek and Lu-Zhe Sun
    Citation: Breast Cancer Research 2020 22:64
  29. Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understandi...

    Authors: Laura A. Baker, Holly Holliday, Daniel Roden, Christoph Krisp, Sunny Z. Wu, Simon Junankar, Aurelien A. Serandour, Hisham Mohammed, Radhika Nair, Geetha Sankaranarayanan, Andrew M. K. Law, Andrea McFarland, Peter T. Simpson, Sunil Lakhani, Eoin Dodson, Christina Selinger…
    Citation: Breast Cancer Research 2020 22:63
  30. African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been...

    Authors: Yara Abdou, Kristopher Attwood, Ting-Yuan David Cheng, Song Yao, Elisa V. Bandera, Gary R. Zirpoli, Rochelle Payne Ondracek, Leighton Stein, Wiam Bshara, Thaer Khoury, Christine B. Ambrosone and Angela R. Omilian
    Citation: Breast Cancer Research 2020 22:62
  31. Mitochondrial dynamics underlies malignant transformation, cancer progression, and response to treatment. Current research presents conflicting evidence for functions of mitochondrial fission and fusion in tum...

    Authors: Brock A. Humphries, Alyssa C. Cutter, Johanna M. Buschhaus, Yu-Chih Chen, Tonela Qyli, Dilrukshika S. W. Palagama, Samantha Eckley, Tanner H. Robison, Avinash Bevoor, Benjamin Chiang, Henry R. Haley, Saswat Sahoo, Phillip C. Spinosa, Dylan B. Neale, Jagadish Boppisetti, Debashis Sahoo…
    Citation: Breast Cancer Research 2020 22:60
  32. Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast can...

    Authors: Ritama Paul, Ming Luo, Xueying Mo, Jason Lu, Syn Kok Yeo and Jun-Lin Guan
    Citation: Breast Cancer Research 2020 22:59

    The Correction to this article has been published in Breast Cancer Research 2020 22:71

  33. Ultrafast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived kinetic parameters have demonstrated at least equivalent accuracy to standard DCE-MRI in differentiating malignant from benign b...

    Authors: Natsuko Onishi, Meredith Sadinski, Mary C. Hughes, Eun Sook Ko, Peter Gibbs, Katherine M. Gallagher, Maggie M. Fung, Theodore J. Hunt, Danny F. Martinez, Amita Shukla-Dave, Elizabeth A. Morris and Elizabeth J. Sutton
    Citation: Breast Cancer Research 2020 22:58
  34. For breast cancer patients undergoing neoadjuvant chemotherapy (NAC), pathologic complete response (pCR; no invasive or in situ) cannot be assessed non-invasively so all patients undergo surgery. The aim of ou...

    Authors: Elizabeth J. Sutton, Natsuko Onishi, Duc A. Fehr, Brittany Z. Dashevsky, Meredith Sadinski, Katja Pinker, Danny F. Martinez, Edi Brogi, Lior Braunstein, Pedram Razavi, Mahmoud El-Tamer, Virgilio Sacchini, Joseph O. Deasy, Elizabeth A. Morris and Harini Veeraraghavan
    Citation: Breast Cancer Research 2020 22:57
  35. Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting...

    Authors: Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michael Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto, Cécile Guillemet, Cristina Alexandru, Maxime Fontanilles, David Sefrioui, Lucie Burel, Sabine Guénot…
    Citation: Breast Cancer Research 2020 22:56
  36. Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Ins...

    Authors: Perrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, Clémence Basse, Sarah Diakite, Aurélien Noret, Audrey Bellesoeur, Vincent Servois, Delphine Hequet, Enora Laas, Youlia Kirova, Luc Cabel, Jean-Yves Pierga, Laurence Bozec, Xavier Paoletti, Paul Cottu…
    Citation: Breast Cancer Research 2020 22:55
  37. Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (NCT...

    Authors: Hee Jeong Kim, Woo Chul Noh, Eun Sook Lee, Yong Sik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyung -Yub Gong, Hwa Jung Kim and Sei Hyun Ahn
    Citation: Breast Cancer Research 2020 22:54
  38. The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the ...

    Authors: Sarocha Chootipongchaivat, Nicolien T. van Ravesteyn, Xiaoxue Li, Hui Huang, Harald Weedon-Fekjær, Marc D. Ryser, Donald L. Weaver, Elizabeth S. Burnside, Brandy M. Heckman-Stoddard, Harry J. de Koning and Sandra J. Lee
    Citation: Breast Cancer Research 2020 22:53
  39. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Lori J. Goldstein, Raymond P. Perez, Denise Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato and Jenny C. Chang
    Citation: Breast Cancer Research 2020 22:52

    The original article was published in Breast Cancer Research 2020 22:4

  40. The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer. We compared the antitumor activity of Z-endoxifen with ta...

    Authors: Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden…
    Citation: Breast Cancer Research 2020 22:51
  41. Alterations in estrogen and progesterone signaling, via their respective receptors, estrogen receptor alpha (ERα) and progesterone receptor (PR), respectively, are largely involved in the development of breast...

    Authors: Henri-Philippe Konan, Loay Kassem, Soleilmane Omarjee, Ausra Surmieliova-Garnès, Julien Jacquemetton, Elodie Cascales, Amélie Rezza, Olivier Trédan, Isabelle Treilleux, Coralie Poulard and Muriel Le Romancer
    Citation: Breast Cancer Research 2020 22:50
  42. Most breast cancer-associated fibroblasts (CAFs) are active and important cancer-promoting cells, with significant impact on patient prognosis. Therefore, we investigated here the role of the protein kinase AT...

    Authors: Mysoon M. Al-Ansari, Maher Al-Saif, Maria Arafah, Abdelmonneim M. Eldali, Asma Tulbah, Taher Al-Tweigeri, Abdelhabib Semlali, Khalid S. Khabar and Abdelilah Aboussekhra
    Citation: Breast Cancer Research 2020 22:49
  43. The human epidermal growth factor receptor (HER) family, notably EGFR, is overexpressed in most triple-negative breast cancer (TNBC) cases and provides cancer cells with compensatory signals that greatly contr...

    Authors: Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang and Roberto R. Rosato
    Citation: Breast Cancer Research 2020 22:48
  44. The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes. There is limited data so far as to (i) how tumor-i...

    Authors: Cornelia Kolberg-Liedtke, Oleg Gluz, Fred Heinisch, Friedrich Feuerhake, Hans Kreipe, Michael Clemens, Benno Nuding, Wolfram Malter, Toralf Reimer, Rachel Wuerstlein, Monika Graeser, Steve Shak, Ulrike Nitz, Ronald Kates, Matthias Christgen and Nadia Harbeck
    Citation: Breast Cancer Research 2020 22:47
  45. The presence of tumour-infiltrating lymphocytes (TILs) is associated with response to neoadjuvant chemotherapy among patients with triple-negative and HER2-positive breast cancer. However, the significance of ...

    Authors: Signe Korsgaard Skriver, Maj-Britt Jensen, Ann Soegaard Knoop, Bent Ejlertsen and Anne-Vibeke Laenkholm
    Citation: Breast Cancer Research 2020 22:46
  46. The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, i...

    Authors: Olga Martínez-Sáez, Nuria Chic, Tomás Pascual, Barbara Adamo, Maria Vidal, Blanca González-Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez, Débora Martínez, Patricia Galván, Ana Belén Rodríguez, Antonio Martinez, Montserrat Muñoz…
    Citation: Breast Cancer Research 2020 22:45
  47. Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black ...

    Authors: Emily J. Gallagher, Kezhen Fei, Sheldon M. Feldman, Elisa Port, Neil B. Friedman, Susan K. Boolbol, Brigid Killelea, Melissa Pilewskie, Lydia Choi, Tari King, Anupma Nayak, Rebeca Franco, Daliz Cruz, Irini M. Antoniou, Derek LeRoith and Nina A. Bickell
    Citation: Breast Cancer Research 2020 22:40

Annual Journal Metrics

  • 2022 Citation Impact
    7.4 - 2-year Impact Factor
    7.4 - 5-year Impact Factor
    1.764 - SNIP (Source Normalized Impact per Paper)
    2.408 - SJR (SCImago Journal Rank)

    2023 Speed
    20 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    2,432,781 downloads
    1,561 Altmetric mentions